Filtered By:
Condition: Anemia
Therapy: Chemotherapy
This page shows you your search results in order of date.
Order by Relevance | Date
Total 22 results found since Jan 2013.
Janssen Data at ASCO GU Support Ambition to Transform Treatment of Prostate and Bladder Cancer Through Precision Medicine and Early Intervention
RARITAN, N.J., February 13, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced plans to present more than 20 abstracts featuring seven oncology therapies from its robust portfolio and pipeline at the annual American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, taking place in San Francisco on February 16-18. Building on more than a decade of leadership in the development of medicines for people diagnosed with GU cancers, Janssen will present data demonstrating its ambition to advance patient-centered treatment through precision medicine, real-world evidence a...
Source: Johnson and Johnson - February 13, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
E-152 Neurointervention in the pediatric population: 18-years experience from a single center
ConclusionsAt out institution, multidisciplinary interaction allowed the treatment of a wide variety of cerebrovascular diseases in the pediatric population. Pediatric patients carry high complication risks due to frequent presence of systemic conditions, but joined experience from pediatric neurology, neurosurgery and neurointervention departments allow their treatment with optimal planning and results.Abstract E-152 Table 1Intracranial aneurysms Variable Value Age at diagnosis, mean (SD) or median (IQR) 16 (16–19) Male:Female 12:10 Associated conditions•Moya moya•Connective tissue disorder•Von Wille...
Source: Journal of NeuroInterventional Surgery - July 23, 2022 Category: Neurosurgery Authors: Donnelly, B., Monteiro, A., Recker, M., Khawar, W., Waqas, M., Cappuzzo, J., Reynolds, R., Siddiqui, A., Levy, E. Tags: SNIS 19th annual meeting electronic poster abstracts Source Type: research
Janssen Data at ASCO GU Demonstrate Longstanding Leadership in Prostate Cancer and Commitment to Advancing Potential New Therapeutic Options for Genitourinary Cancers
Raritan, NJ, Feb. 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that 17 presentations will be featured at the 2022 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, taking place in San Francisco and virtually from February 17-19. Building on its long-term leadership in prostate cancer, Janssen is committed to advancing innovative treatments and transforming patient experiences, while focusing on research that may drive better outcomes for people across the genitourinary cancer spectrum. Data to be presented include Phase 3 results for the selective ...
Source: Johnson and Johnson - February 1, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen Demonstrates Commitment to Advancing Science and Innovation in the Treatment of Solid Tumors at ESMO Annual Congress
September 8, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than ten data presentations from its lung cancer, bladder cancer and prostate cancer portfolio and pipeline will be featured during the European Society for Medical Oncology (ESMO) Annual Congress 2021 virtual meeting, September 16–21. Further details about these data and the science Janssen is advancing will be made available throughout ESMO via the Janssen Oncology Virtual Newsroom.“With a diverse oncology portfolio and pipeline spanning bladder cancer, lung cancer and prostate cancer, Janssen...
Source: Johnson and Johnson - September 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Management of Primary Central Nervous System Lymphoma Using Intra-Arterial Chemotherapy With Osmotic Blood-Brain Barrier Disruption: Retrospective Analysis of the Sherbrooke Cohort
ConclusionCIAC using HD-MTX-based protocols with OBBBD is a safe and well-tolerated procedure for the management of PCNSL. Our data suggests better PFS and survival outcomes compared to IV protocols with less hematologic toxicity and good tolerability, especially in the elderly.
Source: Frontiers in Oncology - January 20, 2021 Category: Cancer & Oncology Source Type: research
NAMPT as a Dedifferentiation-Inducer Gene: NAD+ as Core Axis for Glioma Cancer Stem-Like Cells Maintenance
Conclusion and Perspectives
Gliomas are the most prevalent primary brain cancer in adults and include a broad category of tumors including astrocytoma, oligodendroglioma, and GBM. Regardless of tumor aggressiveness, malignancy, and infiltration, these glia-derived tumors rarely exceed a median survival time of 12–14 months. Driven by the infiltrative nature of these tumors, the clinical approach is difficult and relapses often occur with fatal consequences. These unsuccessful attempts to control glioma's fate have fostered research looking for more effective therapies.
(GSCs) are a small subset of CD133&#...
Source: Frontiers in Oncology - May 2, 2019 Category: Cancer & Oncology Source Type: research
The prognostic value of Red cell distribution width(RDW) in acute pulmonary thromboembolism
Conclusion: High RDW level is associated with higher 30 and 90 days mortality rate in acute PT patients. This marker could be considered as a valuable prognostic factor in acute PE.
Source: European Respiratory Journal - November 19, 2018 Category: Respiratory Medicine Authors: Parsa, S., Hosseinvand, N., Peiman, S. Tags: Pulmonary embolism Source Type: research
New Insights from Studies of Clonal Hematopoiesis.
Abstract
Clonal hematopoiesis (CH) describes an asymptomatic expansion of blood cells descended from a single hematopoietic stem cell. Recent studies have shown that CH increases in frequency with aging, and is often driven by somatic mutations in genes that are recurrently mutated in hematologic malignancies. When CH is associated with a mutation in a leukemia-associated gene at a variant allele frequency of 0.02 or greater, it is termed "clonal hematopoiesis of indeterminate potential" (CHIP). CHIP has a 0.5-1% risk per year of progression to hematological neoplasia, and increases both all-cause mortality and ...
Source: Clinical Cancer Research - April 27, 2018 Category: Cancer & Oncology Authors: Gibson CJ, Steensma DP Tags: Clin Cancer Res Source Type: research
Severe Symptoms, but a Truly Treatable Disease
BY NOURA MAHDI; DARRON LEWIS; JEREMY OSBORNE; & AHMED RAZIUDDIN, MDA 73-year-old man was brought to the emergency department from his nursing home for rectal bleeding and anemia. The patient mentioned he had had episodes of bright red rectal bleeding and constipation for a few months. A colonoscopy had been done prior to the visit, which revealed a large intestine tumor and biopsy confirming adenocarcinoma. He was awaiting an appointment with his surgeon.The patient reported bloody rectal leakage, and a CBC done at the nursing home showed a hemoglobin level of 7.2. He also complained of dyspnea but denied any other ...
Source: The Case Files - March 20, 2018 Category: Emergency Medicine Tags: Blog Posts Source Type: research
Thalidomide-induced Stroke in a Child With Thalassemia Major
We report a case of stroke in a β-thalassemic child who had received a course of thalidomide.
Source: Journal of Pediatric Hematology Oncology - October 26, 2017 Category: Hematology Tags: Online Articles: Clinical and Laboratory Observations Source Type: research
Tumor Treating Fields (TTF) with Triple Chemotherapy for Recurrent Glioblastoma (P1.177)
Conclusions:Therapies with TTF plus TBC demonstrates superior OS benefit for recurrent GBM with moderate, but manageable side effects. A prospective study of TTF plus TBC for recurrent GBM is warranted.Study Supported by: Dr. Marnie Rose FoundationDisclosure: Dr. Zhu has received personal compensation for activities with Novocure, and Prime Oncology. Dr. Zhu has received research support from Novocure, Inc., Five Prime Therapeutics, Immuno-Cellular Inc., DEKK-TEC. Dr. Lu has nothing to disclose. Dr. Rao has nothing to disclose. Dr. Zhu has nothing to disclose.
Source: Neurology - April 17, 2017 Category: Neurology Authors: Zhu, J.-J., Lu, G., Rao, M., Zhu, P. Tags: Neuro-oncology: Gliomas I Source Type: research
Vestibulocochlear nerve dysfunction as initial manifestation of Waldenstrom Macroglobulinemia (P5.193)
Conclusions:Clinical findings from this case demonstrated early vascular complications of multiple peripheral neurosensory systems secondary to WM-related hyperviscosity. Early recognition of symptoms through detailed history taking and neurological examination is necessary for a correct diagnosis and better outcome.Disclosure: Dr. Humayun has nothing to disclose. Dr. Panjwani has nothing to disclose. Dr. Li has nothing to disclose.
Source: Neurology - April 17, 2017 Category: Neurology Authors: Humayun, M., Panjwani, S., Li, H. Tags: Neuro-ophthalmology/Neuro-otology I Source Type: research
Fatal folic acid toxicity in humans - Devnath GP, Kumaran S, Rajiv R, Shaha KK, Nagaraj A.
Folic acid is B-9 vitamin. Folic acid is prescribed commonly for pregnant women to prevent neural tube defects in the fetus, patients under chemotherapy, pernicious anemia and to reduce the risk of stroke and cardiovascular disease. Acute or chronic ingest...
Source: SafetyLit - March 11, 2017 Category: Global & Universal Tags: Home and Consumer Product Safety Source Type: news
Fatal Folic Acid Toxicity in Humans.
Abstract
Folic acid is B-9 vitamin. Folic acid is prescribed commonly for pregnant women to prevent neural tube defects in the fetus, patients under chemotherapy, pernicious anemia and to reduce the risk of stroke and cardiovascular disease. Acute or chronic ingestion of a large dose of folic acid generally manifests as neurological complications, which are reversible. In this present case, a 23-year-old pregnant woman committed suicide by consuming folic acid tablets and succumbed to death within 36 h. Postmortem toxicological analysis detected folic acid in viscera. Death following acute consumption of folic aci...
Source: Journal of Forensic Sciences - March 5, 2017 Category: Forensic Medicine Authors: Devnath GP, Kumaran S, Rajiv R, Shaha KK, Nagaraj A Tags: J Forensic Sci Source Type: research
Atim-18. phase i dose escalation study of d2c7-it administered intratumorally via convection-enhanced delivery (ced) for recurrent malignant glioma (mg)
CONCLUSION:Infusion of D2C7-IT via CED is safe thus far and encouraging efficacy results are observed. Enrollment is ongoing.
Source: Neuro-Oncology - November 6, 2016 Category: Cancer & Oncology Authors: Desjardins, A., Randazzo, D., Chandramohan, V., Sampson, J., Peters, K., Vlahovic, G., Threatt, S., Herndon, J., Boulton, S., Lally-Goss, D., Healy, P., Lipp, E., Friedman, A., Friedman, H., Bigner, D. Tags: ADULT CLINICAL TRIALS (IMMUNOLOGICAL) Source Type: research
